GOSSELIES, Belgium--(BUSINESS WIRE)--Delphi Genetics SA has announced today a new license agreement for the use of the StabyExpress® technology in the food industry. The technology will be used for the production of enzymes for food processing.
Under the agreement, the company receives a non-exclusive worldwide license to use the StabyExpress™ technology for enzyme production in GMP conditions. In exchange, Delphi is eligible to receive upfront and milestone payments associated with the development of the product that utilize the StabyExpress® technology, as well as royalties on sales of such product.
Cédric Szpirer PhD, Delphi Genetics Founder and CEO, explained: “This is Delphi's first licensing agreement that covers the use of the StabyExpress® technology for protein production in the field of food industry. It is an additional proof that the technology is usable for any production of recombinant protein in E. coli including pharmaceutical bioproductions and industrial biotechnology. The StabyExpress® technology allows to produce (i) higher yields of recombinant proteins and (ii) without the use of antibiotic resistance genes. These advantages were clearly identified by our new partner. The non-exclusive nature of this agreement enables us to consider similar collaborations with other strategic partners.”
Previously, Delphi Genetics announced existing licensing agreements with Sanofi-Pasteur, GSK and a subsidiary of Merck & Co., Inc., known as MSD outside the United States and Canada.
StabyExpress® technology can be applied to any industrial protein production process that involves bacterial fermentation. Moreover, the technology is in line with the recommendations of the FDA, USDA and EMA with regard to the elimination of antibiotic resistance genes in protein production processes for both human and veterinary uses. The technology is also usable to produce DNA vaccines in order to avoid completely the use of antibiotics resistance genes.
About Delphi Genetics SA
Founded in 2001, Delphi Genetics develops technologies for DNA and protein productions (including antibodies) by using its unique expertise in the field of plasmid stabilisation systems. Delphi Genetics’ patented StabyExpress® technology increases the yield of recombinant protein or pDNA productions in E. coli without the use of antibiotics, which is the traditional approach. Delphi Genetics is also involved in several research projects including the use of Staby® for the development of DNA vaccines, the adaptation of the technology to mammalian cells and development of antibodies. Delphi Genetics offers licenses, products and value-added services based on its technologies and expertise.
Regarding services, Delphi Genetics provides custom services in genetic engineering in E. coli and mammalian cells, development and productions of proteins, pDNA and antibodies. Antibody development is based on a brand new technology allowing unique antigen presentation to the immune system combined to DNA immunization. Using this method, Delphi Genetics is able to develop antibodies even against self-antigens.
For further information, please visit our website: www.delphigenetics.com